CD40LG and myocardial infarction: For example, in the analysis of a randomized study involving 1088 ACS patients who were either administered abciximab or a placebo, elevated concentrations of sCD40L were indicative of a higher risk of mortality or nonfatal myocardial infarction in the placebo group but not in the abciximab group.[1] Thus, the measurement of sCD40L may have limited utility for assessing risk in patients receiving potent antiplatelet therapy.